Leavitt Chase C. bought 2,000 Mobia Medical shares at $10.30 per share, leaving a reported holding of 5,000 shares. The transaction represents about 40.0% of that resulting position, giving investors a stated measure of the purchase relative to the insider’s post-trade holding.
Key Highlights
- The transaction took place on 11 September 2026.
- The filing reports the transaction under SEC transaction code P.
- Leavitt Chase C.’s resulting position was 5,000 shares, with the purchase representing about 40.0% of that holding.
Mobia Medical, Inc. (NASDAQ: MOBI) saw Leavitt Chase C. buy 2,000 shares at $10.30 per share. The buyer is identified with the designation “SEE REMARKS.
Purchase Recorded on 11 September 2026
Leavitt Chase C. completed the purchase on 11 September 2026. The transaction used code P. The reported position following the transaction was 5,000 shares of Mobia Medical, Inc. The purchase involved the company’s shares at the stated price of $10.30 per share.
Purchase Represents 40.0% of Resulting Holding
The 2,000 shares acquired represent about 40.0% of Leavitt Chase C.’s resulting 5,000-share holding. Mobia Medical, Inc. is identified in the transaction details as NASDAQ: MOBI.
FAQs
Q: How many Mobia Medical shares did Leavitt Chase C. buy?
A: Leavitt Chase C. bought 2,000 Mobia Medical shares at $10.30 per share on 11 September 2026, according to the filing. The transaction was reported under SEC transaction code P.
Q: How large was the Mobia Medical purchase relative to the resulting holding?
A: The 2,000-share purchase represented about 40.0% of Leavitt Chase C.’s resulting 5,000-share holding. The filing reports both the transaction size and the post-transaction share total.
Q: What transaction code was reported for the Mobia Medical purchase?
A: The filing reports the transaction under SEC transaction code P. It also states that Leavitt Chase C. owned 5,000 shares following the transaction.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.